These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 28115844)

  • 1. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
    Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
    Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
    Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
    Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
    Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
    Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro demonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates.
    Bhattarai P; Vance D; Hatefi A; Khaw BA
    J Drug Target; 2017 Jun; 25(5):436-450. PubMed ID: 27937085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells.
    Yi H; Liu L; Sheng N; Li P; Pan H; Cai L; Ma Y
    Biomacromolecules; 2016 May; 17(5):1737-47. PubMed ID: 27029378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance In Vitro and In Vivo.
    Mao X; Si J; Huang Q; Sun X; Zhang Q; Shen Y; Tang J; Liu X; Sui M
    Adv Healthc Mater; 2016 Oct; 5(19):2517-2527. PubMed ID: 27529558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
    Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
    Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
    Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
    Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.
    Li W; Fu J; Ding Y; Liu D; Jia N; Chen D; Hu H
    Acta Biomater; 2019 Sep; 96():456-467. PubMed ID: 31260821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
    Wu Y; Zhou D; Zhang Q; Xie Z; Chen X; Jing X; Huang Y
    Biomacromolecules; 2016 Aug; 17(8):2650-61. PubMed ID: 27384255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
    Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
    Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
    Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
    Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
    Wei Z; Wang H; Xin G; Zeng Z; Li S; Ming Y; Zhang X; Xing Z; Li L; Li Y; Zhang B; Zhang J; Niu H; Huang W
    Int J Nanomedicine; 2020; 15():6545-6560. PubMed ID: 32943867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.